Sareum (LON:SAR) Trading Down 8.8% – What’s Next?

Shares of Sareum Holdings plc (LON:SAR) were down 8.8% during mid-day trading on Tuesday . The company traded as low as GBX 18.20 ($0.24) and last traded at GBX 18.70 ($0.25). Approximately 290,142 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 516,354 shares. The stock had previously closed at GBX 20.50 ($0.27).

Sareum Trading Down 7.3 %

The company’s 50-day simple moving average is GBX 16.10 and its 200 day simple moving average is GBX 22.05. The stock has a market cap of £23.74 million, a P/E ratio of -4.50 and a beta of -1.08.

Sareum (LON:SAR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter. Research analysts anticipate that Sareum Holdings plc will post -3.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sareum news, insider Stephen Parker acquired 84,033 shares of the company’s stock in a transaction on Wednesday, March 26th. The shares were acquired at an average cost of GBX 12 ($0.16) per share, with a total value of £10,083.96 ($13,296.36). 5.02% of the stock is currently owned by corporate insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.